Navigation Links
China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health

BEIJING, June 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its wholly-owned subsidiary, Beijing GP Medical Technologies Co., Ltd. ("GP Medical"), has entered into a strategic collaboration with Gaoxin Da An Healthcare Investment Ltd. ("Da An Health") to co-market and promote molecular diagnostic technologies for clinical diagnostic applications in China. The two parties will also work together to develop new molecular diagnostic products to cater for Da An Health's hospital customers and leverage Da An Health's independent laboratory network for new product validation.

Under the agreement, GP Medical and Da An Health will promote and offer the use of GP Medical's molecular diagnostic products to the customer base of Da An Health. As a result, GP Medical's existing direct sales network covering large hospitals will be expanded to the customer network of Da An Health covering some of the large hospitals that GP Medical did not cover, and large number of mid and small-sized hospitals as well as community hospitals through this strategic collaboration. In addition, the two parties will jointly develop innovative molecular diagnostic product packages or solutions to offer to Da An Health hospital customers. The new product packages or solutions will be validated at the independent laboratories of Da An Health. During the term of the collaboration, the two parties can expand the scope from the molecular diagnostic products to the full product lines of GP Medical and its affiliates in the future.

"We are pleased to establish this strategic collaboration with Da An Health," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We believe this collaboration will promote our brand name as well as product awareness to a new customer base through Da An Health.  We can also get ideas of the hospital demand from this collaboration to prioritize our product development to support our sustainable growth in the future."

"We are excited to become a strategic partner of GP Medical," commented Mr. Yong Zhang, Chief Executive Officer of Da An Health. "Molecular diagnostic market in China has huge potential to grow. Our ability to serve and reach a large number of healthcare institutions which brings each individual hospital demand to a large test volume, complement with GP Medical's outstanding molecular diagnostic product portfolio. Working together, we can better serve a larger number of healthcare institutions in China."

About Gaoxin Da An Healthcare Investment Ltd.Gaoxin Da An Healthcare Investment Ltd. is a China-based leading company engaged in clinical diagnostic testing services and independent laboratory service network in China. With eight clinical test centers serving thousands of hospitals ranging from Tier 1 to Tier 3 as well as community hospitals, Da An Health has one of the largest independent laboratory service networks in China, offering healthcare screening, diagnostic testing and related services. For more information, please visit

About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit

Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. ContactWinnie YamTel: 852-2511-9808Email:

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chinmax Disclaims Liability Following China SFDAs Confirmation that Inverness Medical Beijing is Suspected of Forging SFDA Verification Seal and Approval Date in Submission of Triage BNP Test Registration
2. Nutrastar to Participate in Brean Murray, Carret & Co.s 2011 Beijing China Growth Conference
3. Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
4. China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
5. Altair Semiconductor Successfully Demonstrates its LTE Chipset Speeds and Service for China Mobile Executives
6. China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market
7. Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
8. China Botanic Schedules Conference Call to Discuss FY 2011 Second Quarter Results
9. Reportlinker Adds China Medical Devices Industry - A Market Snapshot and Key Company Profiles
10. Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
11. China Kanghui Holdings Announces Participation in Upcoming Investor Conferences
Post Your Comments:
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
(Date:11/24/2015)... Va. , Nov. 24, 2015  DILON Diagnostics ... have signed an agreement for DILON to distribute GE,s ... across the globe. The signing of this distribution agreement will ... NM750b Molecular Breast Imaging system and is considered an ... provide better healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis ... Care Plan software creates an agreement between the practice owner and the patient ... scheduling, monitoring, notification, and projections. Click here to learn more. ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
Breaking Medicine News(10 mins):